SEC Form 4 · accession 0001104659-17-000627
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
John P Brancaccio
Director
Period of report
Jan 2, 2017
Accepted (ET)
Jan 4, 2017 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jan 2, 2017 | A | 16,667 | A | — | — | Common Stock | 16,667 | 16,667 | D |
Explanation of responses
- F1Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock.
- F2The RSUs shall vest on January 2, 2018.